XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2023
Oct. 31, 2022
Income Statement [Abstract]        
Revenue, Product and Service [Extensible List] Service [Member] Service [Member]    
Oncology services revenue $ 11,573 $ 14,281 $ 24,134 $ 28,026
Costs and operating expenses:        
Cost, Product and Service [Extensible List] Service [Member] Service [Member]    
Cost of oncology services $ 6,618 $ 7,443 14,302 14,495
Research and development 2,515 2,604 5,308 5,491
Sales and marketing 1,795 1,700 3,491 3,392
General and administrative 2,600 2,527 5,540 4,925
Total costs and operating expenses 13,528 14,274 28,641 28,303
Income (loss) from operations (1,955) 7 (4,507) (277)
Other loss (105) (9) (91) (27)
Loss before provision for income taxes (2,060) (2) (4,598) (304)
Provision for income taxes 11 14 39 31
Net loss $ (2,071) $ (16) $ (4,637) $ (335)
Net loss per common share outstanding        
Basic (in dollars per share) $ (0.15) $ 0 $ (0.34) $ (0.02)
Diluted (in dollars per share) $ (0.15) $ 0 $ (0.34) $ (0.02)
Weighted average common shares outstanding        
Basic (in shares) 13,497,061 13,528,643 13,529,629 13,521,496
Diluted (in shares) 13,497,061 13,528,643 13,529,629 13,521,496